Advanced wound care market projected to exceed $15 billion globally by 2030
PERTH, Australia, Feb. 12, 2025 /PRNewswire/ -- Argent BioPharma Ltd. (ASX: RGT) (OTCQB: RGTLF) has made significant progress in its collaboration with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The project leverages nano-encapsulation technology to improve drug efficacy and targeted delivery.
SINTEF, headquartered in Trondheim, Norway, is an independent research organization founded in 1950 that conducts contract research and development projects.
Key Developments:
- Optimizing Antimicrobial Compounds: The company has advanced its proprietary antimicrobial compounds for nano-encapsulation, improving their targeted drug delivery.
- Key Research Milestones Achieved: Standardized in vitro assays have been established, Synthetic Wound Fluid (SWF) identified as the optimal testing medium, and promising active pharmaceutical ingredients (APIs) with pH-dependent antimicrobial activity selected.
- Addressing Critical Wound Care Needs: The initiative focuses on diabetic foot ulcers, pressure sores, post-surgical infections, and potentially non-melanoma skin cancer (NMSC) excisions, aiming to combat biofilm formation, antibiotic resistance, and chronic infections.
Research Progress:
In the project's first phase, Argent BioPharma identified SWF as the most suitable medium for testing antimicrobial efficacy in chronic wound infections. Multiple APIs were screened, revealing promising candidates whose antimicrobial activity is pH-dependent, informing future formulation strategies.
The next phase will refine API combinations for nano-encapsulation and conduct Minimum Inhibitory Concentration (MIC) studies to evaluate synergistic antimicrobial effects. This research aims to develop solutions for persistent infections, biofilm-related complications, and antibiotic resistance.
Market Potential and Strategic Goals:
With the advanced wound care market projected to exceed $15 billion globally by 2030, Argent BioPharma's nano-medicine-driven approach is positioned to transform wound management. The company aims to improve healing outcomes, reduce antibiotic dependency, and expand into oncologic wound care, particularly for post-surgical wounds in NMSC patients.
Commitment to Innovation
Argent BioPharma remains committed to developing innovative therapeutic solutions for unmet medical needs.
for further information please contact:
Argent BioPharma Roby Zomer CEO & Managing Director +61 8 6555 2950 [email protected] | Argent BioPharma Rowan Harland Company Secretary +61 8 6555 2950 [email protected]
|
SOURCE Argent BioPharma Ltd.
